Abstract: Objective Therapeutic outcomes of advanced non-small-cell lung cancer(NSCLC) are not satisfactory，dendritic cells(DCs) vaccine has been developed as a novel strategy against cancer，the aim of this study was to investigate the safty and clinical value of DCs vaccine loaded with heat shock induced apoptotic NSCLC cell lines. Methods A two-armed trial，with 38 patients with stage ⅢB-Ⅳ NSCLC after standard therapy was performed.Peripheral blood mononuclear cells(PBMCs) were separated into adherent cells for induction of DCs loaded with heat shock induced apoptotic NSCLC cell lines.Every week the DCs vaccine was administered intradermally near the inguinal region.The safety and overall survival(OS) were examined. Results DCs vaccine was well tolerated and no obviously toxicity was observed.Although the median survival and the one-year-survival rate of the experiment group were higher than the control group，the statistics showed no significance. Conclusion DCs vaccine for NSCLS is worthy of further study.